Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-08-05
1997-10-14
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514800, 530324, 530397, 530398, A61K 3816, C07K 1700
Patent
active
056772750
ABSTRACT:
Methods useful for treating cancers are disclosed. The methods involve administering human chorionic gonadotropin (hCG) or human luteinizing hormone (hLH) to patients having cancers. Articles of manufacture that are useful for carrying out the described methods are also described. The claimed methods are effective against breast, prostate, ovary, and stomach carcinomas, as well as neuroblastomas, and Kaposi's sarcoma, among others.
REFERENCES:
patent: 5372996 (1994-12-01), Cabrie
Mann et al, Scand. J. Clin. Lab. Invest. , Suppl. vol. 216, pp. 97-104, 1993.
Bidart et al., TEM, vol. 4, No. 9, pp. 285-291, 1993.
Siemen, Rodent Tumor Models in Experimental Cancer Therapy, Edited by Kallman, Pergamon Press, pp. 12-15, 1987.
Trott, Rodent Tumor Models in Experimental Cancer Therapy, Edited by Kallman, Pergramon Press, pp. 6-11, 1987.
Curti, Critical Reviews in Oncology/Hematology, vol.14, pp. 29-39, 1993.
Jain, Scientific American, pp. 58-65, Jul. 1994.
Ross et al., Immunology Today, vol. 11, No. 6, 1990.
Alfthan et al. (1992) Cancer Res. 52: 4628-4633.
Bagshawe (1992) Acta Oncol. 31: 99-106.
Bidart, J-M et al., "Human Chorionic Gonadotropin Molecular Forms, Detection, and Clinical Implications." TEM 4:285 (1993).
Birken, S. et al., "Structure of the Human Chorionic Gonadotropin .beta.-Subunit Fragment from Pregnancy Urine." Endocrinology 123:572 (1988).
Bourinbaiar, A.S. et al., "Inhibitory effect of human chorionic gonadotropin (hCG) on HIV-1 transmission from lymphocytes to trophoblasts." FEBS LETTERS 309:82 (1992).
Bourinbaiar, A.S. et al., "Pregnancy hormones, estrogen and progesterone, prevent HIV-1 synthesis in monocytes but not in lymphocytes." FEBS LETTERS 302:206 (1992).
Chen, W. et al., "Recombinant Carbohydrate Variant of Human Choriogonadotropin .beta.-Subunit (hCG.beta.) Descarboxyl Terminus (115-145)." Journal of Biological Chemistry 266:6246 (1991).
Cole, Laurence A. et al., "The Heterogeneity of Human Chorionic Gonadotropin (hCG). III. The Occurrence and Biological and Immunological Activities of Nicked hCG." Endocrinology 129:1559 (1991).
Cole, L.A., et al., "The Deactivation of hCG by Nicking and Dissociation" Journal of Clinical Endocrinology and Metabolism 76:704 (1993).
Danforth, D.N., Jr., M.D., "How Subsequent Pregnancy Affects Outcome in Women with a Prior Breast Cancer." Oncology 5:23 (1991).
Elford et al. (1993) AIDS 7: 1667-1671.
Freireich, E.J. et al., "Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man." Cancer Chemotherapy Reports 50:219 (1966).
Hirabayashi, M., M.D., "Early Gastric Cancer and a Concomitant Pregnancy", The American Surgeon 53:730 (1987).
Huang, J. et al., "Amino/Carboxyl-terminal Deletion Mutants of Human Choriogonadotropin .beta.." The Journal of Biological Chemistry 268:9311 (1993).
Huang, J. et al., "Mutagenesis of the `determinant loop` region of human choriogonadotropin .beta.." Molecular and Cellular Endocrinology 90:211 (1993).
Kumar, S. et al., "Necrosis and Inhibition of Growth of Human Lung Tumor by Anti-.alpha.-Human Chorionic Gonadotropin Antibody." J. Natl Cancer Inst. 84:42 (1992).
Loosfelt, H. et al., "Cloning and Sequencing of Porcine LH-hCG Receptor cDNA: Variants Lacking Transmembrane Domain." Science 245:525 (1989).
Mann et al. (1993) Scand. J. Clin. Lab. Invest. Suppl. 216: 97-104.
Marcillac et al. (1992) Cancer Res. 52: 3901-3907.
McFarland, K.C. et al., "Lutropin-Choriogonadotropin Receptor: An Unusual Member of the G Protein-Coupled Receptor Family." Science 245:494 (1989).
Nakhai, B. et al., "Over-expression and characterization of recombinant beta subunit of the human chorionic gonadotropin hormone synthesized in insect cells infected with a genetically engineered baculovirus." Indian Journal of Biochemistry & Biophysics 29:315 (1992).
Northfeldt et al. (1991) Hematology/Oncology Clinics of North America 5: 297-310.
Ozturk, M. et al., "Physiological Studies of Human Chorionic Gonadotropin (hCG), .alpha.hCG, and .beta.hCG as Measured by Specific Monoclonal Immunoradiometric Assays." Endocrinology 120:549 (1987).
Ozturk, M. et al., "Ectopic .beta.-Human Chorionic Gonadotropin Production by a Human Hepatoma Cell Line (FOCUS): Isolation and Immunochemical Characterization." Endocrinology 120:559 (1987).
Pierce and Parsons (1981) Ann. Rev. Biochem. 50: 465.
Ryan et al. (1988) FASEB J. 2: 2661-2669.
Sridhar, P. et al., "Differential secretion and glycosylation of recombinant human chorionic gonadotropin (.beta.hCG) synthesized using different promoters in the baculovirus expression vector system." Gene (Netherlands) 131:261 (1993).
Stenman et al. (1993) Scand. J. Clin. Lab. Invest. Suppl. 216: 42-78.
Strickland et al. in Luteinizing hormone action and receptors, M. Ascoli, Ed., CRC Press, Boca Raton FL, 1985, p. 1.
Ward et al. in Reproduction in Domestic Animals, 4th ed., Cuppos, PT, ed., pp. 25-80, Academic Press, NY (1991).
Wass, M. et al., "Response of lymphocytes from cancer patients to human *chorionic* gonadotrophin", Lancet (England) 1:8004:171 (1977).
Yano, T. et al., "Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone." Proc. Natl. Acad. Sci. USA 91:1701 (1994).
Bryant Joseph L.
Gallo Robert C.
Lunardi-Iskandar Yanto
Mohamed Abdel A.
The United States of America as represented by the Department of
Tsang Cecilia J.
LandOfFree
Treatment of cancer with human chorionic gonadotropin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancer with human chorionic gonadotropin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancer with human chorionic gonadotropin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1555303